Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778286 | 0.78 | PSMB8 (0.37) | PSMB8HTTRAB9AGRM2CYP2A6 | |
| SCHEMBL31119206 | 0.76 | PSMB8 (0.38) | PSMB8HTTMAPTCYP2A6CA1 | |
| SCHEMBL1280127 | 0.75 | PSMB8 (0.37) | PSMB8HTTMAPTCYP2A6CA1 | |
| SCHEMBL31109647 | 0.75 | ELANE (0.41) | PSMB8HTTMAPTGRM2CYP2A6 | |
| SCHEMBL1281032 | 0.75 | PSMB8 (0.37) | PSMB8HTTGRM2CYP2A6RORC | |
| SCHEMBL3262100 | 0.74 | PSMB8 (0.41) | PSMB8HTTNPC1MAPTRAB9A | |
| SCHEMBL2794960 | 0.72 | HRH4 (0.36) | NPC1MAPTRAB9AGRM2 | |
| SCHEMBL14327805 | 0.71 | MAPT (0.38) | PSMB8HTTNPC1MAPTRAB9A | |
| SCHEMBL2791481 | 0.71 | F2RL3 (0.42) | PSMB8NPC1MAPTRAB9ACYP2A6 | |
| SCHEMBL13240830 | 0.71 | NPC1 (0.33) | NPC1MAPTRAB9ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168167-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| WO-2010029299-A1 | PYRIMIDINONE DERIVATIES FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2010-03-18 | — | — | WO | disclosed |
| EP-2134686-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008110793-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168167-A1 | Piperidinones Useful in the Treatment of Inflammation | ARG1, ARG2, PRMT1 | PSMB8 3657/4885HTT 2575/4885NPC1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.